Everyone at AMF Medical is keen to see medical technology make a difference. Discover what motivates everyone in this highly skilled and experienced team: a passion for user-centric design combined with innovative microfluidics engineering toward better treatment options.
We know that Sigi™ will be an integral part of our customers’ life: every day, 24/7, year in-year out. This is why, besides safety and security first and foremost, we never settle for less than the best possible ease-of-use in all we do, and perhaps why Sigi™ has been referred to as ‘the Nespresso of insulin patch pumps’.
Antoine Barraud, PhD
Co-CEO and Co-founder
Antoine brings to AMF Medical 18 years experience in the Life Sciences, Space and Watch industries. Specialized in product development and industrialization, he worked during his PhD at EPFL on an insulin micropump and an implantable glucose sensor, which were further developed at Sensile Medical. Antoine holds a Master’s degree in Physics and PhD in Biosensing from EPFL.
Pim van Wesel
Pim is an international MedTech executive, specializing in commercialization and general management for almost 20 years. During his 5-year tenure at Medtronic Diabetes, he developed a strong know-how of the insulin pump market and built a global network among key stakeholders. Prior to earning his MBA from IMD, he worked at ING Corporate Banking. He also holds a Master’s degree in Applied Economics.
Pierre Fridez, PhD
Product Development Director
Pierre has been conceiving and creating Medical Devices for more than 20 years working across all development stages, interweaving his profound engineering expertise with regulatory and clinical research know-how. Highlights of his career include his instrumental role in the success of EndoArt, an EPFL startup sold to Allergan for CHF 120 M, and in the development of EMS’ dental prophylaxis devices which remain commercially successful. He holds a Master’s degree in Physics and a PhD in Biomechanics from EPFL.
Alain has been leading device design, regulatory affairs, and quality teams in MedTech for over 25 years and brings vast experience in Quality Assurance (ISO 13485) and Regulatory Approvals of Medical Devices (CE-marking, FDA) to the development process of Sigi™ . Alain holds a Master’s degree in Physics from the University of Neuchâtel.
Prof. Dr. Peter Ryser
Chairman and Co-founder
Peter Ryser is a co-founder of Sensile Technologies, and was a Professor of Microengineering at the Swiss Federal Institute of Technology in Lausanne for 16 years. Peter holds a PhD. in Applied Physics from the University of Geneva, a Master’s degree in Experimental Physics and an MBA from the University of Applied Sciences in Lucerne. He is also a member of the Swiss Academy of Engineering Sciences.
Investor, Board Member
Ronald Strässler is co-founder of Avaloq Group and architect of the Avaloq Core Banking Suite. Avaloq is a Switzerland-based global leader in digital banking solutions, core banking software and wealth management technology, sold in 2020 for CHF 2 billion to NEC Corporation, a leading Japanese IT group.
Peter Gerhardsson has extensive experience with diabetes therapies. From 1980 to 2000, he held various roles at Novo Nordisk. In 2000, he joined MiniMed, which Medtronic acquired in 2001 and where he continued to lead its European diabetes business. Subsequently, he joined Dexcom as Vice President International Business Development, from 2008 till his retirement in 2018. Thereafter, he joined Institute for Applied Economics and Health Research in Copenhagen as Partner.
John Timberlake has 30+ years of healthcare executive leadership with an accomplished track‐record commercializing diabetes medical devices, drugs, and drug‐device combinations. John is currently CEO of Berkshire Biomedical Corporation, and was previously CEO and Board Member of Valeritas, the original maker of V-Go®, as well as VP at Sanofi, responsible for their U.S. diabetes portfolio, including Lantus®. He earned a Master’s degree in Management from Purdue University, and an MBA from ESC Rouen, France (now NEOMA Business School).
Barry Wilson is a global healthcare executive. He retired as President International with Medtronic Inc, the world’s largest MedTech company. Previously, he served as President of Lederle International (acquired by Pfizer), President of Europe and Intercontinental for Bristol Myers Squibb, and he had 8 international assignments with Pfizer Inc. Barry has an MBA from the Wharton School and an MA from Cambridge University.
Katrin SIEBENBÜRGER Hacki
Katrin Siebenbürger Hacki has over 15 years’ experience in the Medical Device industry where she gained broad expertise in market development, sales force excellence and sales & marketing execution. She is specialized in using healthcare system data to guide product development, go-to-market, international expansion and innovative pricing models for medical technology and diagnostics manufacturers. Katrin holds a MSc in Biotechnology from the École Supérieure de Biotechnologie de Strasbourg (ESBS) and an MBA from IMD in Lausanne.
Dr. med. David Stocker
David supports AMF Medical with over a decade of international experience in diabetes technology, and a strong personal network among experts and other key stakeholders. David has built and scaled up a number of highly successful MedTech start-ups after working as a physician at Zurich University hospital, from which he holds an MD Degree. He advises AMF Medical on matters related to medical affairs, regulatory approvals, market access, and marketing communication.
Doug Lawrence brings 30 years of medical device expertise to AMF Medical, including extensive diabetes know-how acquired as global Vice President of Becton Dickinson’s Insulin Injection business. He holds a Systems Engineering degree from the University of Pennsylvania, and business degrees from the University of Pennsylvania’s Wharton School and Northwestern University’s Kellogg School.